Sertraline for Major Depressive Disorder

What research says

EveryOption research summary

The current ZOLOFT label reports randomized, double-blind, placebo-controlled studies supporting its MDD evidence scope. This bounded assessment does not compare every option or determine personal suitability.

See sourceDailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Source for the opening statement

Relationship: supports bounded conclusion

This statement’s scope

Population: source-defined population

Published supporting passage

The efficacy of ZOLOFT as a treatment for MDD was established in two randomized, double-blind, placebo-controlled studies and one double-blind, randomized-withdrawal study following an open label study in adult (ages 18 to 65) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for MDD (studies MDD-1 and MDD-2).

All published source details

Population: source-defined population
Completeness: Not assessed
Need: Major Depressive Disorder

Source collection coverage: country:US
Source pointer: /sections/1

Open published source

EveryOption’s published assessment

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

Find care

Choose a place to see published offerings. A listing does not confirm current availability.

Choose a place Compare published Treatments for this Need

Why this Treatment appears for this Need

Why this Treatment appears in the Need landscape, separate from the research conclusion.

See relationship sourceDailyMed sertraline (Zoloft) label · checked Oct 16, 2026

Relationship: label-reported clinical studies for the Need